PLK1 and triple-negative breast carcinoma: Targeting of PLK1 using the BI2536 inhibitor in combination with conventional chemotherapy was recently shown to impair tumor growth in vivo in two xenografts models established from biopsies of triple negative breast cancer patients [37].